It occurred to me after several such events this year that virtual meetings create a very different pattern for spectators from live events where we all dash from one hall to another trying to optimise the viewing experience and catch as many key talks as we can.
Instead of the annual rugby scrum in the ASCO poster halls, we can imagine ourselves in an entirely different world with social distancing virtually
Many people will no doubt be eager to listen to the various oral presentations of phase 3 data come Friday morning, while the poor posters may well languish until some undetermined time later, so why not take a step back and highlight some of the early work in developmental therapeutics ahead of time?
In the final part of our ASCO Preview series, we offer our independent take and candid commentary on ten abstracts in developmental therapeutics to watch out for.
A word of warning – we don’t take a particular perspective through the lens of rose tinted glasses, so not all the analyses are positive and there are some firm words against some of the selections regarding continued development or the researchers conclusions/recommendations.
Some of these are agents in early development, some are biomarkers or even emerging trends, but all are intriguing in their own unique fashion.
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from the ASCO meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
Stacking up the various modalities – what do we find?
It’s time to talk about an particular target in AML because there are now a variety of different modalities involved since we last covered it, which makes it rather more intriguing than most. There’s antibodies, ADCs, CAR-T cell therapies, stem cells, and various bispecifics to name a few such examples.
To be clear, we’re not talking about CD123 here either, but rather an entirely different protein that is receiving increasing attention from multiple companies.
How does the evidence stack up? Will one particular approach stand out from all the others?
Next, perhaps what makes this post even more interesting is we have an engaging interview with one of the company CEO’s in this niche to share, so we can see how they view things from the lens of looking at things in a different way from many of the other competitors.
To learn more from our oncology coverage and get a heads up on our latest biotech expert interview, subscribers can log-in or you can click to gain access to BSB Premium Content.
Welcome to SITC19!
National Harbor: It’s time for the first of our daily highlights and review of key data that was presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC).
The first day is usually taken up by some longer review sessions on key topics, intermingled with some rapid fire oral talks on emerging areas where we get to hear some young investigators talk about their ongoing projects.
This results in some broad updates, as well as some specific areas of early R&D in the IO space that often end up as key areas to watch out for over time. This year is no different in that respect…
To learn more from our oncology coverage and get a heads up on our latest insights from the SITC annual meeting, subscribers can log-in or you can click to gain access to BSB Premium Content.
After yesterday’s look at a biotech company (F-star) who are focused on adaptive approaches with bispecific antibodies using checkpoint and immune agonist targets, we now shift direction within Europe to a completely different concept, although both are tetramer-based.
Oncology R&D can be a stop-start journey that is highly unpredictable and uncertain!
In the third part of our latest mini-series on bispecific antibodies, we now take a look a company who are evaluating this modality as a way to activate NK cells and stimulate the innate immune system. With all the fuss and attention on the adaptive immune system and checkpoint blockade, is there a role for innate immunotherapies?
Rather than look at this aspect as competitive, smart companies are seeking ways to complement existing backbones to determine if the outcomes can be boosted by targeting both innate and adaptive systems in a more coordinated manner.
To find out more about these developments, we talked to Dr Adi Hoess, CEO of Affimed, a German biotech company who are developing innate immunotherapies.
They have certainly been on a roller coaster ride of late, with clinical hold and abandonment of a leading program balanced by encouraging initial data with other projects, so what gives?
To learn more and get a heads up on our latest oncology insights and thought leader interview, subscribers can log-in or you can click to gain access to BSB Premium Content.